AlgoTx

AlgoTx

AlgoTx develops novel therapeutic solutions for complex pain

Founded 2018 France

France 9 employees Series B Total: $35.60M Biotechnology, Information Technology +1

AlgoTx is a clinical stage biotechnology company focused on developing targeted therapeutics for peripheral neuropathic pain. The company's lead product, ATX01, is a non-opioid, locally acting treatment designed for Chemotherapy-Induced Peripheral Neuropathy. It has secured Fast-Track designation from the FDA. Currently, the company is conducting the ACT study, a Phase II trial involving over 270 patients, with results expected in early 2025 and plans for an expedited Phase 3 trial. AlgoTx boasts seasoned leadership, a strong international board, and has raised a total of EUR 35 million, including a EUR 20 million Series B round in 2023. Notable investors in the company include Relyens Innovation Santé / Turenne Capital, UI Investissement, Bpifrance through its Innobio 2 fund, Omnes Capital, and angel investors. In addition, in 2023, the company was honored with France Biotech’s ESG HealthTech Trophy for its early commitment to ESG initiatives. Overall, AlgoTx demonstrates promise in addressing a significant medical need with its innovative approach and strong financial backing, making it an intriguing prospect for venture capital investment. For more details, visit the company's website.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	€20.00M	5	Bpifrance, Omnes Capital +3	14 Mar 2023
Grant	€1.00M	1	Bpifrance	14 Mar 2023
Series A	$12.00M	2	Bpifrance, Omnes Capital	24 Nov 2020
Seed Round	€2.60M	1	Bpifrance	20 Nov 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

€20.00M

Bpifrance, Omnes Capital +3

14 Mar 2023

Grant

€1.00M

Bpifrance

14 Mar 2023

Series A

$12.00M

Bpifrance, Omnes Capital

24 Nov 2020

Seed Round

€2.60M

Bpifrance

20 Nov 2019

FAQ About AlgoTx

AlgoTx develops novel therapeutic solutions for complex pain

AlgoTx was founded in 2018.

AlgoTx is headquartered in France.

AlgoTx operates in Biotechnology, Information Technology and Pharmaceutical. Its work centres on Therapeutics, Pain Management, Clinical Research and Neurology. Its customers include Patients with difficult-to-treat 'Complex Pain'.

AlgoTx has approximately 9 employees.

AlgoTx has completed 4 funding rounds, raising a total of $35.60M. The latest funding stage is Series B.

AlgoTx offers: Development of novel non-opioid solutions for complex pain.

Top alternatives and competitors to AlgoTx include Quince Therapeutics, Emmaus Life Sciences, Inc, Ayala Pharmaceuticals . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

AlgoTx and Quince Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About AlgoTx

Services & Products

Target Customers

Funding Rounds & Investors (4)

AlgoTx Alternatives & Competitors

FAQ About AlgoTx